Seeking Alpha

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY...

Nektar Therapeutics (NKTR +0.8%) is a beneficiary of the FDA's approval of Affymax's (AFFY +35.4%) peginesatide treatment of anemia in dialysis patients. Nektar has an exclusive agreement under which it will provide Affymax with its proprietary technology for use in the drug's manufacture in exchange for manufacturing revenue, milestone and other payments.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector